Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06842199 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 9, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Enrollment target: 360 to 383 Study sites: 50 to 46v4 Show 1 more changeShow less
    • Study sites: 50 to 46
  2. Eligibility criteria shortened, about 9 words Study sites revised (50)v3 Show 1 more changeShow less
    • Study sites revised (50)

    See this version in full on ClinicalTrials.gov ↗

  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Feb 2025 to Mar 20, 2025 · Site details revised at 50 of 50 sitesv2 Show 2 more changesShow less
    • Start date changed from estimate of Feb 2025 to Mar 20, 2025
    • Site details revised at 50 of 50 sites
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy, safety, PK characteristics of ICP-488 in Chinese adults with moderate to severe plaque psoriasis.
Trial Details
NCT Number NCT06842199
Lead Sponsor Beijing InnoCare Pharma Tech Co., Ltd.
Conditions Plaque Psoriasis Patients
Enrollment 383 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov